The first rapid swab arrives in the US at a cost of only 5 dollars. It is a test antigenico, and not molecular like the classic swab, which will directly show the result as it happens with some pregnancy testa, and will do so within 15 minutes of the exam.
US, $ 5 test arrives: 150 million orders from Trump
It is the fourth diagnostic support of this type approved by the Food and Drug Administration (Fda), the US agency that authorizes drugs, after the permits granted in emergency between July and August. “This new test, which detects antigens, is an important one new possibility which gives the results in near real time, ”commented Jeff Shuren, director of the FDA’s Center for Equipment and Radiological Health.
The test was patented under the name of BinaxNow by the multinational Abbott. Starting in October, 50 million a month will be produced at a cost of $ 5 a piece and according to the Wall Street Journal, US President Donald Trump is ready to order 150 million samples.
Usa, the 5 dollar test arrives: how it works
Together with the test there is also a technological component, represented by a connected smartphone app, which allows those who are negative to release a kind of temporary digital pass, an “immunity license” indicating the date of the exam, to always have with you and to be able to present every time you undergo test.
This particular tampon is portable and is convenient for use in doctors’ offices, emergency rooms or schools. Specifically, the FDA authorized its use to doctors for suspected patients, within 7 days of the appearance of symptoms attributable to the Covid-19.
However, the US drug agency has specified that, being an antigen test, it is specific for the virus it detects, but not as specific reliable as much as molecular buffers. For this reason, a negative test result is not to be considered 100% reliable and may need confirmation with a diagnosis made by testing. molecular, or in any case it must be contextualized with the patient’s health conditions.
With the approval of the Food and Drug Administration, the stock of the pharmaceutical group Abbot gained 8.5% on Wall Street.
– .
